Lyra Therapeutics amends bylaws to align with universal proxy rules and update stockholder meeting procedures

Lyra Therapeutics, Inc.

Board approved amended bylaws effective Dec 14, 2023, addressing SEC universal proxy Rule 14a-19.
New rules require additional disclosures from stockholders nominating directors or proposing business.
Stockholders soliciting proxies must use a non-white proxy card; obsolete provisions deleted.
Changes are procedural and governance-related; no financial impact disclosed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lyra Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination and proposal procedures, require a non-white proxy card for soliciting stockholders, and delete obsolete provisions with technical changes (effective 2023-12-14).

Change: bylaw amendment
Effective: 2023-12-14

Exact text from the filing

On December 14, 2023, the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-071093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.